WHAT IS ONKO-SURE?
Onko-Sure™ is a simple, non-invasive blood test, which targets a cancer-caused breakdown product. Onko-Sure™ detects a tumor marker that is associated with most cancers. The biological target for the Onko-Sure™ test is abundant and floats-freely in blood (unlike Carcinoembryonic antigen, CEA). Biomarker levels rise dramatically with cancer progression (up to 38 times greater than in normal patients). Onko-Sure™ may become the first "pan tumor" marker in general widespread usage. Onko-Sure™ has international regulatory approvals as a general cancer marker in Taiwan, South Korea, Vietnam, India and Europe (CE Mark certification). In addition, Onko-Sure™ is approved for the detection and monitoring of lung cancer in Canada (Health Canada). In the US, Onko-Sure™ has been cleared to market as a colorectal cancer monitoring test.
ONKO-SURE WEBSITE: http://www.onko-sure.com/
Jury trial has recently been scheduled to be held in November 2013.
Corporate Stock Transfer
3200 Cherry Creek S Dr
Denver, CO 80209-3246
RXPC Security Details
|Market Value1 ||$8,973 ||a/o Feb 15, 2013 |
|Shares Outstanding ||3,686,510,329. ||a/o Feb 27, 2013 |
|Float ||Not Available |
|Authorized Shares ||5 Billion || |
|Par Value ||0.001 |
|Shareholders of Record ||801 ||a/o May 25, 2011 |
Recent News about Onko-Sure & RXPC:
Response from Douglas (to one of RXPC shareholders; Post # 14297)